

EROCIN®

Erythromycin Preparations

COMPOSITION:

Erocin® 500 tablets: Each tablet contains Erythromycin Stearate BP equivalent to Erythromycin 500mg.

Erocin® 250 tablets: Each tablet contains Erythromycin Stearate BP equivalent to Erythromycin 250mg.

Erocin® Forte: Each 5ml after reconstitution contains Erythromycin Stearate USP equivalent to Erythromycin 250mg.

Erocin® Dry mixture: Each 5ml after reconstitution contains Erythromycin Stearate USP equivalent to Erythromycin 125mg.

Erocin® Paediatric Suspension: Each 5ml after reconstitution contains Erythromycin Ethylsuccinate BP equivalent to Erythromycin 250 mg.

Erocin® Dry suspension: Each 5ml after reconstitution contains: Erythromycin Ethylsuccinate BP equivalent to Erythromycin 125 mg.

INDICATIONS:

Erocin® is indicated in the treatment of a wide range of infections caused by or associated with pathogens sensitive to erythromycin therapy.

It is used in conditions such as bronchitis, severe campylobacter enteritis, chancroid, diphtheria, legionnaire's disease and other legionella infections, neonatal conjunctivitis, pertussis, pneumonia (mycoplasmal and other atypical pneumonias). It is also used for the prophylaxis of surgical infections in patients undergoing bowel surgery.

Erocin® is used as an alternative to the penicillins in penicillin-allergic patients with various conditions including anthrax, the prophylaxis of endocarditis, leptospirosis, otitis media, pharyngitis, syphilis, prevention of rheumatic fever, and staphylococcal and streptococcal skin infections.

It is also used as an alternative to the tetracyclines in patients with chlamydial infections such as epididymitis, lymphogranuloma venereum, psittacosis, Q fever, and trachoma and also used in cases of pelvic inflammatory disease and in tularaemia.

DOSAGE AND ADMINISTRATION:

Route of Administration: Oral

Adults and Children over 8 Years:

For mild to moderate infections 2 g daily in divided doses up to 4 g daily in severe infections; 250-500 mg every 6 hours or 0.5-1 g every 12 hours

For acne vulgaris the usual dose is 250 mg three times daily before meals for one to four weeks and then reduced to twice daily until improvement occurs

Children aged 2 to 8 years:

For mild to moderate infections 1 g daily in divided doses; 250 mg every 6 hours

30 mg/kg/day in divided doses. For severe infections up to 50 mg/kg/day in divided doses.

Infants and children up to 2 Years:

For mild to moderate infections 500 mg daily in divided doses; 125 mg every 6 hours

30mg/kg/day in divided doses. For severe infections up to 50 mg/kg/day in divided doses.

PRECAUTIONS, WARNINGS AND SIDE EFFECTS:

1. The preparations should be used with caution in patients with renal and hepatic impairment, and in pregnant and breast-feeding patients.

2. The most frequent adverse-effects occasionally associated with the preparations include nausea, vomiting, abdominal discomfort, diarrhoea, urticaria, rashes and pseudomembranous colitis.

3. Prolonged use of the preparation may result in overgrowth of non-susceptible pathogens including fungi and in such cases appropriate medication should be instituted immediately.

OVERDOSE:

Symptoms: Mainly confined to nausea, vomiting and diarrhea. Treatment: Gastric lavage and general supportive measures.

PROPERTIES AND ACTIONS:

Erocin® contain Erythromycin, a macrolide antibiotic with a bacteriostatic action against many Gram-positive and to a lesser extent some Gram-negative bacteria, as well as other organisms including mycoplasma, spirochaetes, chlamydiae and rickettsiae.

Erythromycin and other macrolides bind reversibly to the 60S subunit of the ribosome, resulting in blockade of the transpeptidation or translocation reactions, inhibition of protein synthesis, and hence inhibition of cell growth. Its action is predominantly bacteriostatic, but high concentrations are slowly bactericidal against the more sensitive strains.

The antimicrobial activity of erythromycin is increased at moderately alkaline pH, especially in Gram-negative species, probably because of the improved cellular penetration of the non-ionised form of the drug.

ANTIMICROBIAL SPECTRUM AND RESISTANCE:

Erocin® is active against the following pathogens:- *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Staphylococcus aureus*, *Bacillus rhusiopathiae*, *Listeria monocytogenes*, *Neisseria meningitidis*, *Neisseria gonorrhoeae* and *Moraxella catarrhalis*. Other organisms usually sensitive to erythromycin include Actinomyces, Chlamydia, Rickettsia and Spirochaetes. Fungi, yeasts, and viruses are resistant to erythromycin.

SHELF LIFE: As per the product label

LEGAL CATEGORY: Prescription only medicines (POM).

STORAGE CONDITIONS: Store in a dry place below 30°C. Protect from light. Keep out of reach of children.

PRESENTATION:

Erocin® 500 tablets: Available in polythene bags packed in tamper proof high density plastic containers of 500's and 1000's and in blister packs of 10 x 10 tablets.

Erocin® 250 tablets: Available in polythene bags packed in tamper proof high density plastic containers of 500's and 1000's and in blister packs of 10 x 10 tablets.

Erocin® Forte: Powder for oral suspension packed in bottles of 60ml & 100ml.

Erocin® dry mixture: Powder for oral mixture packed in bottles of 60ml & 100ml.

Erocin® Paediatric Suspension: Powder for oral suspension packed in bottle of 100ml.

Erocin® dry suspension: Powder for oral suspension packed in bottle of 100ml.

LAST DATE OF REVIEW: July 2019

LICENCE HOLDER: LABORATORY & ALLIED LTD.



Laboratory & Allied Ltd.

Plot No. 209/10349, Mombasa Road,
P.O. Box 42875, Nairobi, Kenya

LTE004-01